| First Author | Jackson LJ | Year | 2012 |
| Journal | Cell Immunol | Volume | 272 |
| Issue | 2 | Pages | 200-13 |
| PubMed ID | 22078270 | Mgi Jnum | J:181378 |
| Mgi Id | MGI:5311102 | Doi | 10.1016/j.cellimm.2011.10.011 |
| Citation | Jackson LJ, et al. (2012) The role of PIM kinases in human and mouse CD4+ T cell activation and inflammatory bowel disease. Cell Immunol 272(2):200-13 |
| abstractText | PIM kinases are a family of three serine/threonine kinases expressed following T cell activation. Using potent selective small molecule antagonists of PIM-1/3 kinases, we demonstrate a potential role for these enzymes in naive and effector CD4+ T cell activation. PIM-1/3 inhibition prevented CD4+ T cell proliferation by inducing a G0/G1 cell cycle arrest without affecting cellular survival. In the absence of PIM-1/3 kinase activity, naive CD4+ T cells failed to fully differentiate into effector cells both in vitro and in vivo. Therapeutic dosing of a PIM-1/3 inhibitor was efficacious in a CD4+ T cell-mediated model of inflammatory bowel disease suggesting that PIM-1 and PIM-3 kinase activity contributes to sustained disease severity. These results demonstrate that PIM-1/3 kinases have an important role in CD4+ T cell responses and inhibition of this activity may provide a therapeutic benefit in T cell-mediated diseases. |
